產(chǎn)品搜索
相關(guān)文章
- CYP2D6基因多態(tài)性用藥指導(dǎo)標(biāo)準(zhǔn)品
- 泛腫瘤大panel質(zhì)控品升級(jí),免費(fèi)試用申請(qǐng)中
- 分享:CIRCULATE-Japan,輔助治療的“升級(jí)”和“降級(jí)”
- PD-1/L1 &4-1BB雙靶點(diǎn)細(xì)胞篩選模型
- 免疫療法對(duì)一類常見白血病顯療效
- “鉆石突變”ALK基因診斷
- 腫瘤免疫藥靶細(xì)胞模型系列——GITR
- 自身免疫疾病潛力靶點(diǎn)——IL-5藥篩細(xì)胞模型
- EBV分子診斷標(biāo)準(zhǔn)品
- 老靶點(diǎn)迭代突破創(chuàng)新:Her2靶點(diǎn)細(xì)胞模型
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73255CSF3R S783fs/BaF3

- 詳細(xì)內(nèi)容
CBP73255 | |
I. Introduction | |
Cell Line Name: | CSF3R S783fs/BaF3 |
Host Cell: | Ba/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS |
Mycoplasma Status: | Negative |
II.Background | |
CSF3R S783fs results in a change in the amino acid sequence of the Csf3r protein beginning at aa 783 of 836, likely resulting in premature truncation of the functional protein (UniProt.org). S783fs does not result in increased Stat3 activation (PMID: 23656643, PMID: 24403076), however, results in increased Src activation and transformation in cell culture (PMID: 23656643), and therefore, is predicted to result in a gain of Csf3r protein function. | |
III. Representative Data | |
1.WB of CSF3R S783fs/BaF3 | |
2. Anti-proliferation assay | |
Figure 2. Anti-proliferation assay of three reference compounds on the CSF3R S783fs/BaF3. |